Conference Reports

By Marielle Fares, PharmD

Washington, DC -- March 8, 2019 -- In patients with moderate-to-severe psoriasis, risankizumab shows superior efficacy to ustekinumab after 52 weeks of treatment, according to an integrated analysis of the phase 3 UltlMMa-1 and UltlMMa-2 trials presented here at...

By Marielle Fares, PharmD

Washington, DC -- March 8, 2019 -- Certolizumab offers a durable long-term response to plaque psoriasis over 96 weeks, according to an open-label extension of the phase 3 CIMPASI-1 and CIMPASI-2 trials presented here at the 2019 Annual Meeting of the American...

By Marielle Fares, PharmD

Washington, DC -- March 8, 2019 -- Bimekizumab, a selective and potent inhibitor of interleukin (IL)-17A and IL-17F, shows rapid, effective, and safe results with long-term, subcutaneous dosing every 4 weeks, according to a study presented here at the 2019 Annual...

By Marielle Fares, PharmD

Washington, DC -- March 8, 2019 -- Continuous risankizumab, an interleukin (IL)-23 inhibitor, is safe and superior to adalimumab therapy for treatment of patients with moderate-to-severe psoriasis, as is switching from adalimumab to risankizumab, according to...

By Marielle Fares, PharmD

Washington, DC -- March 8, 2019 -- Patients with moderate-to-severe psoriasis maintain a long-term 75% reduction in Psoriasis Activity and Severity Index score (PASI75) with secukinumab, an interleukin 17A (IL-17A) monoclonal antibody, according to a study...

By Jenny Powers

PARIS -- September 18, 2018 -- Adding methotrexate to adalimumab increased the response in patients with psoriasis who demonstrated a previous suboptimal response to adalimumab monotherapy, according to results of a single-arm, open-label, longitudinal study of 46 patients...

By Jenny Powers

PARIS -- September 18, 2018 -- Tildrakizumab provided significant improvements to the Dermatology Life Quality Index (DLQI) that were sustained up to 64 weeks in patients with moderate-to-severe psoriasis, according to results from a post hoc pooled analysis of data from...

By Jenny Powers

PARIS -- September 18, 2018 -- Tildrakizumab is highly effective in patients with moderate to severe plaque psoriasis regardless of whether they had received prior biologic therapy, according to findings from a post hoc pooled analysis of data from the reSURFACE-1 and...

By Jenny Powers

PARIS -- September 18, 2018 -- Patients with moderate to severe psoriasis treated with risankizumab for 16 weeks showed superior responses that remained consistent across baseline demographics and disease characteristics, according to findings from a pooled, retrospective...

By Jenny Powers

PARIS -- September 17, 2018 -- Patients with plaque psoriasis who failed to respond to initial treatment with etanercept appear to show response to certolizumab pegol, researchers reported here at the 27th Congress of the European Academy of Dermatology and Venereology (...

Pages